BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28389388)

  • 1. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
    Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
    Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Fluorescent Peptide Toxin for Selective Visualization of the Voltage-Gated Potassium Channel K
    Wai DCC; Naseem MU; Mocsár G; Babu Reddiar S; Pan Y; Csoti A; Hajdu P; Nowell C; Nicolazzo JA; Panyi G; Norton RS
    Bioconjug Chem; 2022 Nov; 33(11):2197-2212. PubMed ID: 36330854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
    Rashid MH; Huq R; Tanner MR; Chhabra S; Khoo KK; Estrada R; Dhawan V; Chauhan S; Pennington MW; Beeton C; Kuyucak S; Norton RS
    Sci Rep; 2014 Mar; 4():4509. PubMed ID: 24676092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats.
    Bergmann R; Kubeil M; Zarschler K; Chhabra S; Tajhya RB; Beeton C; Pennington MW; Bachmann M; Norton RS; Stephan H
    Sci Rep; 2017 Jun; 7(1):3756. PubMed ID: 28623364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases.
    Jin L; Zhou QT; Chan HK; Larson IC; Pennington MW; Morales RAV; Boyd BJ; Norton RS; Nicolazzo JA
    J Pharm Sci; 2016 Feb; 105(2):650-656. PubMed ID: 26869426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa.
    Jin L; Boyd BJ; Larson IC; Pennington MW; Norton RS; Nicolazzo JA
    J Pharm Sci; 2016 Jul; 105(7):2173-9. PubMed ID: 27312508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1[R14A], a K
    Reddiar SB; Jin L; Wai DCC; Csoti A; Panyi G; Norton RS; Nicolazzo JA
    Toxicon; 2021 May; 195():29-36. PubMed ID: 33689790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of Microglial Kv1.3 Potassium Channels by the Peptide HsTX1[R14A] Attenuates Lipopolysaccharide-mediated Neuroinflammation.
    Nicolazzo JA; Pan Y; Di Stefano I; Choy KHC; Reddiar SB; Low YL; Wai DCC; Norton RS; Jin L
    J Pharm Sci; 2022 Mar; 111(3):638-647. PubMed ID: 34767826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Kv1.3 K
    Varga Z; Tajti G; Panyi G
    Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Administration of the Kv1.3-Blocking Peptide HsTX1[R14A] Improves Cognitive Performance in Senescence Accelerated SAMP8 Mice.
    Pan Y; Kagawa Y; Sun J; Lucas DSD; Takechi R; Mamo JCL; Wai DCC; Norton RS; Jin L; Nicolazzo JA
    Neurotherapeutics; 2023 Jul; 20(4):1198-1214. PubMed ID: 37226029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K
    Veytia-Bucheli JI; Jiménez-Vargas JM; Melchy-Pérez EI; Sandoval-Hernández MA; Possani LD; Rosenstein Y
    Cell Commun Signal; 2018 Aug; 16(1):45. PubMed ID: 30107837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Biodistribution Study of the Radiolabeled Kv1.3-Blocking Peptide DOTA-HsTX1[R14A] Demonstrates Brain Uptake in a Mouse Model of Neuroinflammation.
    Reddiar SB; de Veer M; Paterson BM; Sepehrizadeh T; Wai DCC; Csoti A; Panyi G; Nicolazzo JA; Norton RS
    Mol Pharm; 2023 Jan; 20(1):255-266. PubMed ID: 36331024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
    Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
    Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.
    Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C
    J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis.
    Tanner MR; Pennington MW; Chauhan SS; Laragione T; Gulko PS; Beeton C
    Arthritis Res Ther; 2019 Jan; 21(1):6. PubMed ID: 30612588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
    Ye F; Hu Y; Yu W; Xie Z; Hu J; Cao Z; Li W; Wu Y
    Toxins (Basel); 2016 Apr; 8(4):115. PubMed ID: 27104568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
    Beeton C; Pennington MW; Norton RS
    Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
    Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
    FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.
    Pucca MB; Bertolini TB; Cerni FA; Bordon KC; Peigneur S; Tytgat J; Bonato VL; Arantes EC
    Immunology; 2016 Feb; 147(2):240-50. PubMed ID: 26595158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
    Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
    J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.